Načítá se...

Sporadic adenomatous polyp regression with exisulind is effective but toxic: a randomised, double blind, placebo controlled, dose‐response study

BACKGROUND AND AIM: A 12 month, multicentre, randomised, double blind, placebo controlled, phase 3, dose‐response study was carried out. Exisulind inhibits tumour growth by induction of apoptosis. The aim of our study was to investigate if exisulind induces regression of sporadic colonic adenomas. P...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Arber, N, Kuwada, S, Leshno, M, Sjodahl, R, Hultcrantz, R, Rex, D
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Group 2006
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1856089/
https://ncbi.nlm.nih.gov/pubmed/16150858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gut.2004.061432
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!